Artiva Biotherapeutics Inc. (ARTV)

$11.77 -0.23 (-1.92%)
Market Cap N/A
Revenue (ttm) 33.49M
Net Income (ttm) -27.70M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 342,500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vascul...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 267 4467
Address:
5505 Morehouse Drive, Suite 100, San Diego, United States
lovestockstwits
lovestockstwits Apr. 2 at 11:44 AM
$ARTV everyday up
0 · Reply
swinda42
swinda42 Apr. 1 at 10:32 PM
$ARTV come on go to 25$ already
0 · Reply
swinda42
swinda42 Apr. 1 at 1:01 PM
$ARTV
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 31 at 10:11 PM
$ARTV
0 · Reply
Think_Bigly
Think_Bigly Mar. 31 at 6:45 PM
$ARTV very few even know about this.. with RMAT from FDA.. will come to market.. https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
hbkstockislife
hbkstockislife Mar. 31 at 3:59 PM
$ARTV At this rate 100$ before data ..every day up
0 · Reply
DonnaTroy
DonnaTroy Mar. 31 at 1:40 AM
$ARTV
0 · Reply
hbkstockislife
hbkstockislife Mar. 30 at 2:09 PM
$ARTV when xbi down 3-4% it’s barely down ..when xbi up .20% it’s up 10% ..best stock
0 · Reply
lovestockstwits
lovestockstwits Mar. 30 at 2:03 PM
$ARTV eveyday green everyday
0 · Reply
dule2021
dule2021 Mar. 29 at 7:38 PM
$ARTV story is great on this one but the bar for success is high isnt it? Can this -80% on not meeting the bar?
0 · Reply
Latest News on ARTV
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 10, 2026, 4:05 PM EDT - 26 days ago

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 5 weeks ago

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Feb 24, 2026, 8:00 AM EST - 5 weeks ago

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Feb 19, 2026, 8:00 AM EST - 6 weeks ago

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Jan 21, 2026, 8:00 AM EST - 2 months ago

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored

Jan 15, 2026, 8:02 PM EST - 2 months ago

Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Nov 12, 2025, 7:20 AM EST - 5 months ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:00 AM EST - 5 months ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Nov 3, 2025, 4:05 PM EST - 5 months ago

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Oct 30, 2025, 4:17 PM EDT - 5 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Oct 16, 2025, 4:05 PM EDT - 6 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 25, 2025, 4:05 PM EDT - 7 months ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Aug 6, 2025, 4:05 PM EDT - 8 months ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 4:05 PM EDT - 11 months ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

May 13, 2025, 4:05 PM EDT - 11 months ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 11 months ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Apr 28, 2025, 4:35 PM EDT - 1 year ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Jan 29, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Aug 13, 2024, 2:14 PM EDT - 1 year ago

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22, 2024, 3:55 PM EDT - 1 year ago

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ACTU ARDT CON LINE OS QMMM TWFG

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

Jul 18, 2024, 7:08 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

lovestockstwits
lovestockstwits Apr. 2 at 11:44 AM
$ARTV everyday up
0 · Reply
swinda42
swinda42 Apr. 1 at 10:32 PM
$ARTV come on go to 25$ already
0 · Reply
swinda42
swinda42 Apr. 1 at 1:01 PM
$ARTV
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 31 at 10:11 PM
$ARTV
0 · Reply
Think_Bigly
Think_Bigly Mar. 31 at 6:45 PM
$ARTV very few even know about this.. with RMAT from FDA.. will come to market.. https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
hbkstockislife
hbkstockislife Mar. 31 at 3:59 PM
$ARTV At this rate 100$ before data ..every day up
0 · Reply
DonnaTroy
DonnaTroy Mar. 31 at 1:40 AM
$ARTV
0 · Reply
hbkstockislife
hbkstockislife Mar. 30 at 2:09 PM
$ARTV when xbi down 3-4% it’s barely down ..when xbi up .20% it’s up 10% ..best stock
0 · Reply
lovestockstwits
lovestockstwits Mar. 30 at 2:03 PM
$ARTV eveyday green everyday
0 · Reply
dule2021
dule2021 Mar. 29 at 7:38 PM
$ARTV story is great on this one but the bar for success is high isnt it? Can this -80% on not meeting the bar?
0 · Reply
OwlKing
OwlKing Mar. 29 at 5:44 PM
$BTQ & $ARTV !
0 · Reply
TradeWithCreed
TradeWithCreed Mar. 27 at 8:26 PM
$NKTR $VWAV $ARTV $BTQ bioplay
0 · Reply
MrBruceWayne
MrBruceWayne Mar. 27 at 1:19 PM
🚨 BUY ALERT $ARTV
0 · Reply
topstockalerts
topstockalerts Mar. 26 at 1:06 PM
Pre Market Top Gainers PT2 $VGAS $ARTV $FOXX $BOXL $MLEC
0 · Reply
UltimateRampageBulls
UltimateRampageBulls Mar. 24 at 11:13 PM
$ARTV whens the next cat?
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 24 at 6:00 PM
$ARTV Q4 '25 Earnings Results & Recap Artiva Biotherapeutics expects existing cash, cash equivalents, and investments of $108M to fund planned operating expenses and capital expenditure requirements into the second quarter of 2027.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Mar. 24 at 4:40 PM
$ARTV Took a 2% position, BIG upside if it hits in Q2, will probably run up a lot before readout
0 · Reply
thesheiktrader
thesheiktrader Mar. 23 at 3:45 PM
$RCKT guys check $ORKA $ARTV
1 · Reply
BiotechValues
BiotechValues Mar. 17 at 5:27 PM
$ARTV HUGE hints just posted today on EULAR online program. Three presentations listed for early June. "Robust and durable clinical responses...in severe RA" and "highly effective in severe Sjogren Disease" (company hinted this is next indication). Exciting couple months ahead!
0 · Reply
swinda42
swinda42 Mar. 13 at 3:08 PM
$ARTV why is this dropping so bad today
0 · Reply
AnomalyDetective
AnomalyDetective Mar. 13 at 1:53 PM
$ARTV
0 · Reply
jacksparo
jacksparo Mar. 12 at 11:45 PM
$ARTV It got to almost 7.74 yesterday! From my December 21th email! Almost 110% proft from suggested entry in the email! Everything documented! Check the attached images!
0 · Reply